Circulating tumour-cell count used to decide between treatments for breast cancer patients

Bookmark and Share
Published: 12 Dec 2018
Views: 818
Rating:
Save
Dr Francois-Clement Bidard - Institut Curie, Paris, France

Dr Francois-Clement Bidard gives a press conference at SABCS 2018 about the results from the phase III STIC CTC trial, where circulating tumour-cell count was used to decide between hormone therapy or chemotherapy for patients with metastatic, ER , HER2- breast cancer.

Watch our interview with Dr Bidard here.

Read more about this work here.